The Eli Lilly and Company Distinguished Scholar in Critical Care Medicine
In the fall of 2006, Kalpalatha K. Guntupalli, MD, FCCP, was selected as the Second Eli Lilly and Company Distinguished Scholar in Critical Care Medicine. Dr. Guntupalli is Professor and Acting Chief, Pulmonary/Critical Care and Sleep Section and Director of Pulmonary, Critical Care, and Critical Care Fellowship Programs at Baylor College of Medicine in Houston, Texas. In addition, she is Associate Chief of Medicine, Chief of Pulmonary/Critical Care/Sleep and Director of the Medical Intensive Care Unit at Ben Taub General Hospital, also in Houston. Her project is "Development and Validation of the Educational Materials for Use by the Critical Care Health-care Team (Physician Trainees, Nurses, Respiratory Therapists, Physician Assistants) and Patient/Family for Use in the Critical Care Units."
The GlaxoSmithKline Distinguished Scholar in Respiratory Health
In the summer of 2007, Sidney S. Braman, MD, FCCP, was selected as the Second GlaxoSmithKline Distinguished Scholar in Respiratory Health. Dr. Braman is Division Director of Pulmonary and Critical Care Medicine at the Warren Albert Medical School of Brown University in Providence, Rhode Island. His project is “The ACCP Chronic Care Model for COPD and Its Comorbidities: An Initiative for Primary Care Physicians and Other Health-care Providers To Improve the Quality of Life and Health Outcomes for Patients With COPD.”
The GlaxoSmithKline Distinguished Scholar in Thrombosis
The ACCP, The CHEST Foundation, and GlaxoSmithKline created the GlaxoSmithKline Distinguished Scholar in Thrombosis in 2003. In funding another Distinguished Scholar, GlaxoSmithKline continues to reflect the importance of developing new scientific discoveries in the area of thrombosis and enhancing their endeavors in educating physicians in clinical practice. The award is intended to permit the investigation of issues that are not easily supported by traditional funding, such as the development of public policy, patient education models, or economic analysis of treatment or care delivery to patients with thromboembolism. The Second GlaxoSmithKline Distinguished Scholar in Thrombosis will be selected in July 2008 and receive $50,000 every year over his or her 3-year term as the Distinguished Scholar. In her or her fourth year, the Distinguished Scholar will serve as mentor to the third Distinguished Scholar and receive $10,000. Applications for awards are now closed. DEADLINE: APRIL 30, 2008